A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Patients will receive oral MRX2843 for 28 days to study the side effects, tolerability and
best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.